Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 95, Issue 6, Pages -Publisher
WILEY
DOI: 10.1002/jmv.28823
Keywords
antiviral agents; coronavirus; SARS coronavirus
Categories
Ask authors/readers for more resources
This systematic review and meta-analysis aimed to determine the efficacy of statins in hospitalized patients with COVID-19. Seven RCTs met the inclusion criteria, but there was no significant difference in mortality, length of hospital stay, ICU admission, and mechanical ventilation between the statin group and the control group. Statins may not be effective in reducing adverse outcomes in hospitalized COVID-19 patients.
This systematic review and meta-analysis aimed to determine the efficacy of statins in hospitalized patients with coronavirus disease-2019 (COVID-19). A systematic search was made of PubMed, Embase, Cochrane Library, and , without language restrictions. Randomized controlled trials (RCTs) on treatment of COVID-19 with statins, compared with placebo or standard of care, were reviewed. Seven RCTs (enrolling 1830 participants) met the inclusion criteria. There was no statistically significant difference in all-cause mortality (risk ratio [RR]: 0.92, 95% confidence interval [CI]: 0.75-1.13), length of hospital stay (weighted mean difference: -0.21 days, 95% CI: -1.01 to 0.59 days), intensive care unit (ICU) admission (RR: 1.84, 95% CI: 0.45-7.55), and mechanical ventilation (RR: 1.09, 95% CI: 0.70-1.70) between the two groups. Statins failed to reduce mortality, ICU admission, mechanical ventilation, and length of stay in hospitalized patients with COVID-19. Statins probably should not be used routinely in COVID-19 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available